Strides Pharma Science climbed 1.28percent to R S 416.60 as a result of its Singapore-based subsidiary, Strides Pharma Global, received US FDA approval for butalbital, acetaminophen, caffeine, and codeine phosphate capsules.

According to IQVIA MAT May 2020 statistics, the US market for butalbital, acetaminophen, caffeine, and codeine phosphate capsules, and 50 mg/325 mg/40 mg/30 mg, is now approximately US$ 10 million. The product will be marketed with Strides Pharma Inc. at the US market, the corporation said in an BSE filing made before market hours today (9 July 20 20 ).

The company includes 124 cumulative abbreviated new drug application (ANDA) filings with United States Food &amp; Drug Administration (USFDA), which 87 ANDAs are approved and 3-7 are pending consent.

Strides Pharma Science is a worldwide pharmaceutical firm. It targets on difficult to fabricate products that are sold in more than 100 nations.